HomeCompareMDT vs HRC

MDT vs HRC: Dividend Comparison 2026

MDT yields 3.31% · HRC yields 11.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HRC wins by $2.20M in total portfolio value
10 years
MDT
MDT
● Live price
3.31%
Share price
$85.74
Annual div
$2.84
5Y div CAGR
29.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.3K
Annual income
$9,789.15
Full MDT calculator →
HRC
HRC
● Live price
11.38%
Share price
$155.96
Annual div
$17.74
5Y div CAGR
40.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.26M
Annual income
$1,423,429.65
Full HRC calculator →

Portfolio growth — MDT vs HRC

📍 HRC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDTHRC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDT + HRC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDT pays
HRC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDT
Annual income on $10K today (after 15% tax)
$281.55/yr
After 10yr DRIP, annual income (after tax)
$8,320.78/yr
HRC
Annual income on $10K today (after 15% tax)
$966.88/yr
After 10yr DRIP, annual income (after tax)
$1,209,915.20/yr
At 15% tax rate, HRC beats the other by $1,201,594.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDT + HRC for your $10,000?

MDT: 50%HRC: 50%
100% HRC50/50100% MDT
Portfolio after 10yr
$1.16M
Annual income
$716,609.40/yr
Blended yield
62.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MDT right now

MDT
Analyst Ratings
1
Strong
26
Buy
22
Hold
Consensus: Buy
Price Target
$111.45
+30.0% upside vs current
Range: $100.00 — $120.00
Altman Z
2.9
Piotroski
7/9
HRC
Analyst Ratings
7
Buy
12
Hold
1
Sell
Consensus: Hold
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDT buys
0
HRC buys
0
No recent congressional trades found for MDT or HRC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDTHRC
Forward yield3.31%11.38%
Annual dividend / share$2.84$17.74
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR29.3%40.3%
Portfolio after 10y$54.3K$2.26M
Annual income after 10y$9,789.15$1,423,429.65
Total dividends collected$29.9K$2.14M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold

Year-by-year: MDT vs HRC ($10,000, DRIP)

YearMDT PortfolioMDT Income/yrHRC PortfolioHRC Income/yrGap
1← crossover$11,128$428.29$12,296$1,595.93$1.2KHRC
2$12,483$575.94$15,730$2,573.05$3.2KHRC
3$14,138$780.71$21,147$4,316.00$7.0KHRC
4$16,196$1,068.46$30,235$7,608.15$14.0KHRC
5$18,809$1,479.09$46,615$14,263.36$27.8KHRC
6$22,201$2,075.70$78,712$28,834.27$56.5KHRC
7$26,716$2,960.69$148,063$63,841.01$121.3KHRC
8$32,891$4,305.30$315,890$157,462.80$283.0KHRC
9$41,599$6,405.16$778,498$440,495.17$736.9KHRC
10$54,300$9,789.15$2,256,422$1,423,429.65$2.20MHRC

MDT vs HRC: Complete Analysis 2026

MDTHealthcare

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Full MDT Calculator →

HRCStock

Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000 systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.

Full HRC Calculator →
📬

Get this MDT vs HRC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDT vs SCHDMDT vs JEPIMDT vs OMDT vs KOMDT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.